USCOM LIMITED — Share Issue/Capital Change 2021

Aug 23, 2021

==> picture [53 x 64] intentionally omitted <==

ASX MEDIA RELEASE

Issue of shares to employees

SYDNEY, Australia, Tuesday 24 August 2021: Uscom Limited (ASX code: UCM) (the Company or Uscom ) today notified the market that it has resolved to pay a one-off equity bonus to its full-time employees in Australia and New Zealand in recognition of their very significant contribution to the Uscom business which has resulted in the year ended 30 June 2021 being the first year in which the Company has achieved being operational cash-flow positive.

The Company will issue the following:

• eight employees will be issued with a total of 568,966 fully paid ordinary shares for nil consideration. The shares will not be subject to escrow or any other restrictions.

• one employee will be issued with 200,000 performance rights. The employee may convert the rights to 200,000 fully paid ordinary shares at nil consideration provided he continues to be employed by Uscom as at 1 July 2022. Other terms of the performance rights are set out in the Uscom Limited Equity Incentive Plan previously approved by shareholders.

In addition, 200,000 fully paid shares will be issued to the Company’s employee in Beijing, being the quarterly salary payment.

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks. The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

==> picture [53 x 64] intentionally omitted <==

ASX MEDIA RELEASE

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. The SpiroSonic spirometers, FLO , SMART , and AIR , require no calibration, are durable, simple to disinfect, and are simple, inexpensive and accurate to use providing research quality pulmonary function testing in hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobileSpiroSonic APP and proprietary SpiroSonic software, SpiroReporter , with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of asthma, COPD, sleep disordered breathing, industrial lung disease and COVID monitoring for pulmonary fibrosis.

VENTITEST: Digital ultrasonic ventilator calibration solution is a new system for calibrating ventilators. All ventilators and respiratory support devices require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S , based on advanced SpiroSonic technology provides a calibration solution that provides for simple and accurate calibration, archiving, analysis and reporting and optimal ventilation performance.

For more information, please visit: www.uscom.com.au

Authorised by: Rob Phillips Brett Crowley Executive Chairman Company Secretary rob@uscom.com.au

This announcement is approved for release to the ASX by the Board of Uscom Limited.

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au